Viral Vectors for Gene Therapy

Biotechnology

Volumn 5, Issue , 2008, Pages 395-425

  Carter, Barrie J ^a  

^a Targeted Genetics Corporation   (United States)

Author keywords

Efficiency; Eliminating; Inability; Optimization; Toxicology

Indexed keywords

EID: 0001194531     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620869.ch18     Document Type: Chapter

References (91)

1. AFIONE, S. A, CONRAD, C. K., KEARNS, W. G, CHUNDURU, S, ADAMS, R. et al. (1996), In vivo model of adeno-associated virus vector persistence and rescue, J Virol. 70, 3235-3241.
2. ALLEN, J. A, DEBELAK, D. J, REYNOLDS, T. C, MILLER, A. D. (1997), Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homologous recombination during AAV vector production, J. Virol. 71, 6816-6822.
3. ANDERSON, F. W. (1993), What about those monkeys that got T-cell lymphoma? Hum. Gene Ther. 4, 1-2.
4. ARMENTANO, D, ZABNER, J, SACKS, C, SOOK-DEO, C. C, SMITH, M. P. et al. (1997), Effect of the E4 regions on the persistence of transgene expression from adenovirus vectors, J. Virol. 71. 2408-2416.
5. BERGELSON, J, CUNNINGHAM, J. A, DROGUETT G, KURT-JONES, E. A, KRITHIVAS A. et al. (1997), Isolation of a common receptor for cox-sackie B viruses and adenoviruses 2 and 5, Science 275, 1320-1323.
6. BERKNER, K. L. (1988), Development of adenovirus vectors for the expression of heterologous genes, Biotechniques 6, 616-626.
7. BERNS, K. I. (1990), Parvoviridae and their replication, in: Virology (FIELDS, B. N, KNIPE, D. M, et al, Eds.), pp. 1743-1764. New York: Raven Press.
8. BERNS, K. I, GIRAUD, C. (Eds.) (1996), Adeno-Associated Virus (AAV) Vectors in Gene Therapy, Current Topics in Microbiology in Microbiology and Immunology. Berlin: Springer-Verlag.
9. BLACKLOW, N. R. (1988), Adeno-associated viruses of humans, in Parvoviruses and Disease (PATTISON, J. R, Ed.), pp. 165-174. Boca Raton, FL: CRC Press.
10. BLAESE, M, BLANKENSTEIN, T, BRENNER, M, COHEN-HOGUENAUER, O, GANSBACHER, B. et al. (1995), Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 2, 291-297.
11. BRENNER, M. K. (1995), Human somatic gene therapy: progress and problems, J. Intern. Med. 237, 229-239.
12. BROUGH, D, LIZANOVA, A, Hsu, C, KULESA, V. A, KOVESDI, I. (1996), A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions El and E4, J. Virol. 70, 6497-6501.
13. BUNNELL, B. A, MORGAN, R. A. (1996), Retrovi-rus-mediated gene transfer, in: Viral Genome Methods (ADOLPH, K. W, Ed.), pp. 3-23. Boca Raton, FL: CRC Press.
14. CARTER, B. J. (1989a), The growth cycle of adeno-associated virus, in Handbook of Parvoviruses, Vol. I. (TJISSEN, P, Ed.), pp. 155-168. Boca Raton, FL: CRC Press.
15. CARTER, B. J. (1989b), Parvoviruses as vectors, in Handbook of Parvoviruses, Vol. II (TJISSEN, P, Ed.), pp. 155-168. Boca Raton, FL: CRC Press.
16. CARTER, B. J. (1992), Adeno-associated virus vectors, Curr. Opin. Biotechnol. 3, 533-539.
17. CARTER, B. J. (1996), The promise of adeno-associated virus vectors, Nature Biotechnology 14, 1725-1726.
18. CARTER, B. J, MENDELSON, E, TREMPE, J. P. (1989), AAV DNA replication, integration and genetics, in: Handbook of Parvoviruses, Vol. I (TJISSEN, P, Ed.), pp. 169-226. Boca Raton, FL: CRC Press.
19. CHENGVALA, M. V. R, LUBECK, M. D, SELLING, B. J., NATUK, R. J., Hsu, K. L. et al. (1991), Adenovirus vectors for gene expression, Curr. Opin. Biotechnol. 2,718-722.
20. CLARK, K. R, VOULGAROPOULOU, F, FRALEY, D. M, JOHNSON, P. R. (1995), Cell lines for the production of recombinant adeno-associated virus, Hum. Gene Ther. 6, 1329-1341.
21. COFFIN, J. (1984), Structure of the retroviral genome, in: RNA Tumor Viruses, 2nd Edn. (WEISS, R, TEICH, N, VARMUS, H, COFFIN, J, Eds.), pp. 261-368. New York: Cold Spring Harbor Laboratory Press.
22. COLOSI, P., ELLIGER, S, ELLIGER, C, KURTZMAN, G. (1995), AAV vectors can be efficiently produced without helper virus, Blood 86, 627a.
23. CONRAD, C. K, ALLEN, S. S, AFIONE, S. A, REYNOLDS, T. C, BECK, S. E. et al. (1996), Safety of single-dose administration of an adeno-associated virus (AAV-CFTR) vector in the primate lung, Gene Ther. 3, 658-668.
24. CRYSTAL, R. G. (1995), Transfer of genes to humans: early lessons and obstacles to succes, Science 270, 404-410.
25. DANOS, O, MULLIGAN, R. C. (1988), Safe and efficient generation of recombinant retrovirus with amphotropic and ecotropic host ranges, Proc. Natl. Acad. Sci. USA 85, 6460-6464.
26. FLANNERY, J.G., ZOLOTUKHIN, S, VAQUERO, M.I, LA VAIL, M. M, MUZYCZKA, N, HAUS-WIRTH, W. W. (1997), Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA 94, 6916-6921.
27. FLOTTE, T. R, CARTER, B. J. (1995), Adeno-associated virus vectors for gene therapy, Gene Ther. 2, 357-362.
28. FLOTTE, T. R, AFIONE, S. A, SOLOW, R, MCGRATH, S. A, CONRAD, C. et al. (1993a), In vivo delivery of adeno-associated vectors expressing the cystic fibrosis transmembrane conductance regulator to the airway epithelium, Proc. Natl. Acad. Sci. USA 93, 10163-10617.
29. FLOTTE, T. R, ZEITLIN, P. L, SOLOW, AFIONE, S, OWENS, R. A. et al. (1993b), Expression of the cystic fibrosis transmembrane conductance regular from a novel adeno-associated virus promoter, J. Biol. Chem. 268, 3781-3790.
30. FLOTTE, T. R, BARRAZZA-ORTIZ, X, SOLOW, R, AFIONE, S. A, CARTER, B. J, GUGGINO, W. B. (1995), An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction, Gene Ther. 2, 39-47.
31. GARZIGLIA, M. K, KODAN, M. J, YEI, S, LIM, J, LEE, G. M. et al. (1996), Elimination of both El and E2A from adenovirus vectors further improves prospects for in vivo human gene therapy, J. Virol. 70, 4173-4178.
32. HALL, F. L. (1997), Targeting retroviral vectors to vascular lesions by genetic engineering of the Mo-MLV qp70 envelope protein, Hum. Gene Ther. 8, 2183-2192.
33. HANENBERG, H, XIAO, X. L, DILLOO, D, HA-SHINO, K, KATO, I, WILLIAMS, D. A. (1996), Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells, Nature Medicine 2, 876-882.
34. HAVENGA, M, HOOGERBRUGGE, P, VALERIO, D., VAN ES, H, H. G. (1997), Retroviral stem cell gene therapy, Stem Cells 15, 162-179.
35. HEHIR, K, ARMENTANO, D. M, CARDOZA, L. M, CHOQUETTE, T. L, BERTHELETTE, P. B. et al. (1996), Molecular characterization of replication-competent variants of adenovirus vector and genome modifications to prevent their occurrence, J. Virol. 70, 8459-8467.
36. HALBERT, C L, STONDAERT, T. A, AITKEN, M. L, MERANDER, I. E, RUSSELL, R. W, MILLER, A. D. (1997), Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence and administration, J. Virol. 71, 5932-5941.
37. HERZOG, R. W, HAGSTROM, J. N, KUNG, S. H, TAI, S. J, WILSON, J. M. et al. (1997), Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA 94, 5804-5805.
38. HITT, M. M, ADDISON, C. L, GRAHMAM, F. L. (1997), Human adenovirus vectors for gene transfer into mammalian cells, in: Advances in Pharmacology Vol. 40 (AUGUST, T, Ed.), pp. 137-206. San Diego, CA: Academic Press.
39. HOCH, R. A, MILLER, A. D, OSBORNE, W, R. A. (1989), Expression of human adenovirus deaminase from various strong promoters after gene transfer into human hematopoietic cell lines, Blood 74, 876-881.
40. HORWITZ, M. S. (1990a), Adenoviruses, in: Virology, 2nd Edn. (FIELDS, B. N, KNIPE, D. M, Eds.), pp. 1723-1740. New York: Raven Press.
41. HORWITZ, M. S. (1990b), Adenoviruses and their replication, in: Virology, 2nd Edn. (FIELDS, B. N, KNIPE, D. M., Eds.), pp. 1679-1721. New York: Raven Press.
42. HUYGHE, B. G, LIU, X, SUTJIPTO, S, SUGARMAN, B. J, HORN, M. T. et al. (1995), Purification of type 5 recombinant adenovirus encoding human p53 by column chromatography, Hum. Gene Ther. 6, 1403-1416.
43. JAFFEE, E. M, DRANOFF, G, COHEN, L. K, HAUDER, K. M, MULLIGAN, R. C, PARDOL, D. (1993), High-efficiency gene transfer into primary human tumor explants without cell selection, Cancer Res. 53, 2221-2226.
44. JOLLY, D. (1994), Viral vector systems for gene therapy, Cancer Gene Ther. 1, 51-64.
45. JOLLY, D, WERNER, J. (1997), Anti-vector immunoglobulin induced by retroviral vectors, Hum. Gene Ther. 8, 1263-1273.
46. KAPLAN, J. M, SMITH, A. E. (1997), Transient immunosuppression with deotyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung, Hum. Gene Ther. 8, 1095-1104.
47. KAPLITT, M. G, LEONE, P, SAMULSKI, R. J., XIAO, X, PFAFF, D. et al. (1994), Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain, Nature Genetics 8, 148-154.
48. KASAHARA, N. A., DOZY, A. M, KAN, Y. W. (1994), Tissue-specific targeting of retroviral vectors through ligand receptor interactions, Science 266, 1373-1376.
49. KAY, M. A, HOLTEMAN, A.-X., MEUSE, L, GOWEN, A, OCHS, H. D.et al. (1995), Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4 Ig administration, Nature Genetics 11, 191-195.
50. KEARNS, W. G, AFIONE, S. A., FULMER, S. B, PANG, M. G, ERIKSON, D. et al. (1996), Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line, Gene Ther. 3, 748-755.
51. KESSLER, P. D., PODSAKOFF, G. M, CHEN, X., MCQUISTON, S. A, COLOSI, P. C. (1996), Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein, Proc. Natl. Acad. Sci. USA 93, 14082-14087.
52. KOTIN, R. M. (1994), Prospects for the use of adeno-associated virus as a vector for human gene therapy, Hum. Gene Ther. 5, 793-801.
53. KOZAK, M. (1987), At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells, J. Mol. Biol. 196, 94-950.
54. LEBKOWSKI, M, NALLY, M. A, OKARMES, T. (1992), Production of recombinant adeno-associated virus vectors, U.S. Patent 5173414.
55. LIEBER, A, HE, C. Y., KIRILLOVA, I, KAY, M. A. (1996), Recombinant adenovirus with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vivo and in vivo, J. Virol. 70, 8944-8960.
56. LINDEN, R. M., WARD, P, GIRAUD, C, WINOCOUR, E, BERNS, K. I. (1996), Site-specific integration by adeno-associated virus, Proc. Natl. Acad. Sci. USA 93, 11288-11294.
57. LOUIS, N, EVELEGH, C, GRAHAM, F. L. (1997), Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line, Virology 233, 423-429.
58. MARKOWITZ, D, GOFF, S, BANK, A. C. (1988), Construction and use of a safe and efficient am-photropic packaging cell line, Virology 167, 400-406.
59. MCCORMACK, J. E., MARTINEAU, D, DEPOLO, N., MAIFERT, S, AKABARION, L. et al. (1997), Anti-vector immunoglobin induced by retroviral vectors, Hum. Gene Ther. 8, 1263-1273.
60. MILLER, A. D. (1996), Cell-surface receptors for retroviruses and implications for gene transfer, Proc. Natl. Acad. Sci. USA 93, 11407-11413.
61. MILLER, A. D, BUTTIMORE, C. (1986), Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production, Mol. Cell. Biol. 6, 2895-2902.
62. MILLER, A. D, ROSMAN, G. J. (1989), Improved vectors for gene transfer and expression, Bio-techniques 7, 980-985.
63. MILLER, A. D, GARCIA, J. V, VON SUHR, N, LYNCH, C, WILSON, C, EDEN, M. V. (1991), Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus, J. Virol. 65, 2220-2224.
64. MITTEREDER, N., MARCH, K. L, TRAPNELL, B. C. (1996), Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy, J. Virol. 70, 7498-7509.
65. MULLIGAN, R. C. (1991), Gene Transfer and Gene Therapy: Principles, Prospects and Perspective, Etiology of Human Disease at the Human Level (LINDSTEIN, J, PETTERSSON, U., Eds.), pp. 143-189. New York: Raven Press.
66. MUZYCZKA, N. (1992), Use of adeno-associated virus as a generalized transduction vector in mammalian cells, Curr. Top. Microbiol. Immunol. 158, 97-129.
67. NGUGEN, D, WIEHLE, S, KOCH, P, BRANCH, C, YEN, N. et al. (1997), Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus DNA complex, Cancer Gene Ther. 4, 191-198.
68. ORLIC, D, GIRARD, L. J, JORDAN, C. T, ANDERSON, S. M, CLINE, A. P, BOCLINE, D. M. (1996), The level of mRNA encoding the am-photropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction, Proc. Natl. Acad. Sci. USA 93, 11097-11102.
69. ORY, D. S, NEUGEBORN, B. A., MULLIGAN, R. C. (1996), A stable human-derived packaging cell line for production of high-titer retrovirus/vesic-ular stomatitis virus pseudotypes, Proc. Natl. Acad. Sci. USA 93, 11400-11406.
70. PEREIRA, D. J, MUZYCZKA, N. (1997),The adeno-associated virus type 2 p40 promoter requires a proximal Spl interaction and a pl9 CArG-like element to facilitate Rep transactivation, J. Virol. 71, 4300-4309.
71. RAM, Z, CULVER, K. W, OSHIRO, E. M, VIOLA, J. J, DE VROOM, H. L. et al. (1997), Therapy of malignant Grain tumors by intratumoral implantation of retroviral vector producing cells, Na-ture Medicine 3, 1354-1361.
72. RIDDELL, S. R, ELLIOT, M, LEWINSOHN, D, GILBERT, M. J, WILSON, L. et al. (1996), T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients, Nature Medicine 2, 216-222.
73. ROSENFELD, M. A., COLLINS, F. S. (1996), Gene therapy for cystic fibrosis, Chest 109, 241-252.
74. ROSENFELD, M. A, SIEGFRIED, W, YOSHIMURA, K, YONEYAMA, K, FUKAYAMA, M. et al. (1991), Adenovirus-mediated transfer of recombinant alphal-antitrypsin gene to lung epithelium in vivo, Science 252, 431-434.
75. SALMONS, B, GUNZBURG, W. (1993), Targeting of retroviral vectors for gene therapy, Hum. Gene Ther. 4, 129-141.
76. SAMULSKI, R. J, CHANG, L. S, SHENK, T. E. (1989), Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression, J. Virol. 63, 3822-3828.
77. SHABRAM, P. W., GIROUX, D, GOUDREAU, A. M., GREGORY, R. J, HORN, M. T. et al. (1997), Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles, Hum. Gene Ther. 8, 453-465.
78. SMITH, A. E. (1995), Viral vectors in gene therapy, Annu. Rev. Microbiol. 49, 807-838.
79. SMUDA, J. W., CARTER, B. J. (1991), Adeno-associated viruses having nonsense mutations in the capsid gene: growth in mammalian cells containing an inducible amber suppressor, Virology 184, 310-318.
80. SONG, W, KONG, H. L, TRAKTMAN, P., CRYSTAL, R. (1997), Cytotoxic T lymphocyte responses to proteins coded by heterologous transgenes transferred in vivo by adenoviral vectors, Hum. Gene Ther. 8, 1207-1217.
81. TAMAYOSE, K, HIRAI, Y, SHIMADA, T. (1996), A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vector by using packaging cell lines and sulfonated cellulose column chromatography, Hum. Gene Ther. 7, 507-513.
82. WEITZMAN, M. D, KYOSTIO, S. R. M, KOTIN, R. M, OWENS, R. A. (1994), Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA, Proc. Natl. Acad. Sci. USA 91, 5808-5812.
83. WILSON, J. (1996), Adenoviruses as gene-delivery vehicles, N. Engl. J. Med. 334, 1185-1187.
84. WILSON, C. A., No, T. H, MILLER, A. E. (1997), Evaluation of recommendations for replication competent retrovirus testing associated with use of retroviral vectors, Hum. Gene Ther. 8, 869-874.
85. WILSON, D, MERRITT, J, CLAYMAN, G., SWISHER, S, NEMUNAITIS, J. et al. (1998), Clinical gene therapy strategies: phase I/II results with adenoviral p53 (INGN 201) gene transfer in advanced head and neck and non-small cell lung cancer. Presentation at 1st American Society of Gene Therapy, Seattle, Washington, May 1998.
86. XIAO, X, Li, J, SAMULSKI, R. J. (1996), Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector, J. Virol. 70, 8098-8108.
87. XIAO, X, Li, J, MCCOWN, T. J, SAMULSKI, R. J. (1997), Gene transfer by adeno-associated virus vectors into the central nervous system, Exp. Neurol. 144, 113-124.
88. YANG, Q, CHEN, F., TREMPE, J. P. (1994), Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins, J. Virol. 68, 4847-4856.
89. YANG, Y, Li, Q, ERTL, H. C. J, WILSON, J. (1995), Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirues, J. Virol. 69, 2004-2015.
90. YANG, YM, SU, Q, GEROD, I. S, SCHILZ, R, FLAVELL, R. A, WILSON, J. M. (1996), Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues, J. Virol. 70, 6370-6377.
91. ZUFFEREY, R, NAGY, D, MANDEL, R. J, NAL-DINI, L, TRONO, D. (1997), Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo, Nature Biotechnology 15, 871-875.